|Articles|April 1, 2019

Accelerate. Scale. Implement.

BioReliance® End-to-End Solutions encompass service and support for both emerging biotech as well as major biopharmaceutical companies that seek to accelerate process development, clinical drug production, and conceptual facilities design.

BioReliance® End-to-End Solutions encompass service and support for both emerging biotech as well as major biopharmaceutical companies that seek to accelerate process development, clinical drug production, and conceptual facilities design.  We facilitate success by enabling our clients at any step from early-stage Process Development through commercial Facilities Design-anywhere in the world -having flexible solutions that optimize performance and providing guidance based upon first-hand experience. We operate our own in-house bioproduction facilities and convey our expertise to clients as they progress along their drug development journey.

 

MilliporeSigma
CPhI North America Booth #907


Related to this article

The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.